Baron Wealth Management LLC raised its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 1.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,926 shares of the medical instruments supplier’s stock after buying an additional 35 shares during the quarter. Baron Wealth Management LLC’s holdings in West Pharmaceutical Services were worth $631,000 as of its most recent filing with the SEC.
A number of other large investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC increased its stake in shares of West Pharmaceutical Services by 18.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier’s stock worth $78,000 after acquiring an additional 38 shares during the period. Covestor Ltd boosted its holdings in West Pharmaceutical Services by 14.3% in the 3rd quarter. Covestor Ltd now owns 320 shares of the medical instruments supplier’s stock valued at $96,000 after purchasing an additional 40 shares in the last quarter. KBC Group NV increased its position in West Pharmaceutical Services by 0.4% during the 4th quarter. KBC Group NV now owns 9,980 shares of the medical instruments supplier’s stock worth $3,269,000 after purchasing an additional 42 shares during the period. UMB Bank n.a. raised its stake in shares of West Pharmaceutical Services by 1.2% during the 3rd quarter. UMB Bank n.a. now owns 3,941 shares of the medical instruments supplier’s stock worth $1,183,000 after buying an additional 47 shares in the last quarter. Finally, Kensington Investment Counsel LLC raised its stake in shares of West Pharmaceutical Services by 2.8% during the 3rd quarter. Kensington Investment Counsel LLC now owns 1,752 shares of the medical instruments supplier’s stock worth $526,000 after buying an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.
Analysts Set New Price Targets
WST has been the topic of a number of recent analyst reports. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Bank of America boosted their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Citigroup initiated coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price target for the company. Finally, Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $430.20.
West Pharmaceutical Services Trading Down 0.9 %
Shares of WST stock opened at $340.07 on Thursday. The stock has a market cap of $24.63 billion, a P/E ratio of 50.46, a P/E/G ratio of 18.59 and a beta of 1.00. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $413.70. The business has a fifty day simple moving average of $330.44 and a 200-day simple moving average of $313.87.
West Pharmaceutical Services Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th will be issued a dividend of $0.21 per share. The ex-dividend date is Friday, February 7th. This represents a $0.84 annualized dividend and a yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.46%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
- Five stocks we like better than West Pharmaceutical Services
- Canadian Penny Stocks: Can They Make You Rich?
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
- There Are Different Types of Stock To Invest In
- As China Tightens Rare Earth Exports, These 3 Stocks Are in Focus
- What is a buyback in stocks? A comprehensive guide for investors
- Rebuilding the Empire: Can Dollar General Rally in 2025?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.